Having in mind the demonstrated positive correlation between CSF IL-6 detectability and disease activity in our RR-MS patients, we compared the distribution of detectable CSF IL-6 between active RR-MS patients and controls. This evidence concerns the gene IL6 and myeloid sarcoma.